Radiation Oncology

Non-small cell lung cancer   

Questions discussed in this category

Do the results of the unplanned subset analysis of the PACIFIC trial showing no OS benefit in this population lean you away from consolidation?

Does tumor location play a role (central vs peripheral) in making the decision?  The question stems from an oral presentation at ASTRO 2014 inves...

In patients who have a mixed response or progression and are poor candidates for other systemic agents, would you consider consolidating the chest? Wo...

NCCN recommends annual CT surveillance indefinitely after year 5, but I’m curious how many physicians continue and for how long?

Do you recommend or make any modifications in the PACIFIC regimen for patients > 75 years of age?

In clinical practice, consolidation chemotherapy is sometimes used, though this was not implemented in the PACIFIC trial. https://www.ncbi.nlm.nih.go...

How do you prescribe a steroid taper? If it is grade 2, would you keep them on low dose prednisone while continuing? When do you feel comfortable re-c...

Rate of pneumonitis was low in the PACIFIC trial but does it mirror the real world setting? We are seeing increased pneumonitis in our practice.

Do you feel it is important to start durvalumab within 14 days of completing cCRT?  What real life challenges do you face in doing so and wh...

Medical inoperability is clearly defined, anatomical resectability is also pretty much clear (invasion of trachea/carina/esophagus, etc). But what abo...

If you are using a standard 30/10 fractionation, is there a benefit to keeping chemo on board for radio-sensitization?

The EGFR subgroup appeared not have benefited as much as other patients in the publication. However, recently it was reported that the PACIFIC study m...

For example, would you modify your SBRT dose next to the azygous vein? While we talk frequently about OAR constraints for the great vessels, it seems ...

I am treating a left lower lobe NSCLC and my PTV is so close to the spleen that a small portion of the spleen is getting significant dose.  I can...

As a for instance, a centrally located primary tumor with mediastinal adenopathy that results in a TE fistula? Currently we would recommend esophagea...

What would you anticipate with regard to potential adrenal toxicity when the patient has only 1 functioning adrenal gland? There are no other sites of...

Does EGFR+ status influence your decision? What is the significance of this finding and its potential for progression? Is it simply occult disease con...

I see the LungTECH trial dose constraints, but, they seem really conservative when you have something large and close the PBT resulting in use of 60 G...

Since the randomized phase II data from Gomez et al presented at ASTRO 2018 showed a survival benefit, is there concern about randomizing patients to ...

Does it factor into your decision making in the setting of restricted spirometry and normal lung volumes? Does this differ for SBRT v. chemoRT?

If a patient clearly has N1 disease with high SUV on PET, do you routinely recommend EBUS or mediastinoscopy to evaluate for N2 disease?

If there is no other evidence of metastatic disease, would you offer thoracic radiation? Either upfront with chemo or after initial system therapy if ...

Would your answer differ based on whether the patient is receiving concurrent chemotherapy? Are there other factors that would influence this decision...

Do you prefer breath-hold techniques (ABC, DIBH) or abdominal compression regardless of tumor motion? Or do you use a general threshold number of cc's...

In a patient with a cavitated lesion with underlying chronic infection (identified as cocci) and SqCC, are there additional risks to SBRT? Should spec...

In patients with aberrant anatomy due to previous surgery with lung PTV overlapping the stomach, how much would you dose de-escalate? Even conventiona...

If so, what constraint is most clinically relevant? The EORTC LungTech trial (60Gy/8 fractions) does not specify a chest wall constraint. I have...

For example, would a + vascular margin, extranodal extension of N1 disease, translobar disease, or high risk histologies (large cell neuroendocrine, s...

Do you discuss this at the first consultation? Is there strong evidence to suggest that risks are significantly increased compared to upfront lobectom...

Do you prefer carboplatin-paclitaxel-bevacizumab, carboplatin-pemetrexed-pembrolizumab, or chemotherapy alone?

Is local control worse for SBRT when the tumor is invading into the bone (rib)?

Specifically in O2-dependent patients? Have any dose/fractionation regimens been shown to reduce the risk of pneumonitis in this population?

I recently saw a patient who had been treated with concurrent pembrolizumab-RT elsewhere. Is this an acceptable practice outside the setting of a clin...

For example, a NSCLC of the LLL abutting and potentially involving the adventitia of the descending aorta?

For a patient with a new contralateral primary or recurrence and previous pneumonectomy, what lung constraints do you prioritize (ex mean lung dose, V...

When would you favor delivering local therapy (e.g. SBRT) prior to systemic therapy?

If you treat pre-chemotherapy volumes, is there a benefit to induction chemotherapy even in bulky disease. If so, how do you define disease that ...

What factors influence your decision (R1 v. R2 resection? T stage?) If sequential, do you typically prefer radiation before or after chemotherapy?

Is there a role for SBRT to the primary site? Is it required to treat the ipsilateral hilum if no adenopathy was seen on EBUS or PET?

Have you ever seen toxicity related to diaphragm dose with conventional fractionation?  

Papers discussed in this category

J Clin Oncol, 2006 Oct 20

Cancer, 1998 Mar 15

Int J Radiat Oncol Biol Phys, 2012 Nov 1

JAMA, 2010 Mar 17

Int J Radiat Oncol Biol Phys, 2017 Mar 15

Int J Radiat Oncol Biol Phys, 2015 Nov 15

Radiother Oncol, 2013 Aug

Radiother Oncol, 2016 Oct

Int J Radiat Oncol Biol Phys, 2016 Dec 1

Pract Radiat Oncol, 2018 Apr 10

J Clin Oncol, 2005 Sep 1

J Clin Oncol, 2007 May 1

Med. Pediatr. Oncol.,

J. Clin. Oncol.,

N Engl J Med, 2017 Nov 16

N Engl J Med, 2015 Sep 27

Lancet, 2016 Dec 13

Lancet Oncol, 2016 Nov

N. Engl. J. Med., 2018 Apr 16

Int J Radiat Oncol Biol Phys, 2009 Apr 1

J. Clin. Oncol.,

Clin Lung Cancer, 2016 Nov

Int J Radiat Oncol Biol Phys, 2006 Jul 1

Int J Radiat Oncol Biol Phys, 2007 Oct 1

N. Engl. J. Med., 2018 Sep 25

Radiat Oncol, 2015 Apr 26

Clin Lung Cancer, 2017 Jul 10

J Thorac Oncol,

Clin Lung Cancer, 2018 Feb 17

Int. J. Radiat. Oncol. Biol. Phys., 2017 Mar 15

Radiother Oncol, 2016 Jun

J Clin Oncol, 2008 Dec 10

Int J Radiat Oncol Biol Phys, 2007 Feb 1

J Clin Oncol, 2015 Sep 1

Int J Radiat Oncol Biol Phys, 2012 May 1

Int J Radiat Oncol Biol Phys, 2012 Feb 1

Int J Radiat Oncol Biol Phys, 2010 Mar 1

J Radiosurg SBRT,

Lancet Oncol, 2017 Jul

Int J Radiat Oncol Biol Phys, 2017 Jun 1

JAMA Oncol,

J Thorac Oncol, 2015 Aug

Clin Lung Cancer, 2015 Nov

Am. J. Clin. Oncol., 2007-06-01

Medicine (Baltimore),

Eur Radiol, 2016 Mar 04

Med Phys, 2011 Nov

Clin Lung Cancer, 2017 Mar

Int. J. Radiat. Oncol. Biol. Phys., 2010-06-01

Int. J. Radiat. Oncol. Biol. Phys., 2012 Jul 24

Respir. Res., 2018 Apr 24

Int J Radiat Oncol Biol Phys, 2011 Oct 1

Int J Radiat Oncol Biol Phys, 2012 Jun 1

Int. J. Radiat. Oncol. Biol. Phys., 2008 Jan 30

Thorac Surg Clin,

Int J Radiat Oncol Biol Phys, 2012 Dec 19

Int J Radiat Oncol Biol Phys, 2014 Apr 1

Int J Radiat Oncol Biol Phys, 2015 Sep 1

N. Engl. J. Med.,

PLoS ONE, 2015 Nov 24

Lancet, 2009 Aug 1

J. Clin. Oncol., 2015 Nov 02

JAMA Oncol, 2019 Apr 25

Future Oncol, 2019 Apr 25

Int J Radiat Oncol Biol Phys, 2018 Mar 15

J Thorac Oncol, 2019 Feb 16

N Engl J Med, 2011 Aug 4